氯氮平所致的静坐不能及其相关因素

Akathisia and clozapine in schizophrenic patients

为探讨氯氮平（ＣＺＰ）治疗所致静坐不能的发生率及其相关因素，对２１６例单独服用ＣＺＰ治疗的精神分裂症患者采用修改的Ｓｉｍｐｓｏｎ锥体外系副反应量表评定静坐不能，进行为期８周的前瞻性研究。结果显示，ＣＺＰ治疗所致的静坐不能发生率为１２．９６％，多数发生于治疗的１～３周，使用心得安治疗效果良好；静坐不能的发生与ＣＺＰ治疗剂量和入院时ＢＰＲＳ总分有关，而与性别、年龄、病程等因素无关。作者认为，ＣＺＰ治疗能够引起静坐不能，发生率可能低于氯丙嗪等经典抗精神病药物，其危险因素有待进一步的研究揭示。

Objective:To study the prevalence and factors associated with akathisia in schizophrenic patients after clozapine treatment. Method:216 schizophrenic patients treated with clozapine was assessed for akathisia with the modified Simpsons extrapyramidal side effect rating scale for eight weeks following treatment.Mental state of patients were monitored with the Brief Psychiatric Rating Scale (BPRS). Results:The prevalence rate was 1296% with the first three weeks most frequent.Akathisia was positively correlated with the dosage of clozapine and the BPRS score before treatment.No relationship was found with sex,age and course of the illness.Propanolol was effective in relieving akathisia. Discussion:Prevalence of akathisia caused by clozapine was probably lower than chlorpromazine.Other risk factors require further study.